GSK ends $2.2 billion brain drug partnership with Alector after trial failures

GSK and California‑based biotech Alector have ended their collaboration after both experimental brain drugs failed to meet development milestones.

The partnership, announced in July 2021, gave GSK rights to two Alector candidates for a total upfront payment of $700 million and the possibility of up to $1.5 billion in additional payments if key milestones were achieved.

Latozinemab, the later‑stage candidate, did not significantly slow disease progression in a large late‑stage study released last October. The early‑stage drug nivisnebart was dropped after an interim futility analysis in a Phase 2 trial for early Alzheimer’s disease.

A new securities filing confirms the alliance has been terminated, ending what had been a potential $2.2 billion deal for GSK’s return to neuroscience.